Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | IDE | P14735 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228430 | 0.85 | L3MBTL1 (0.50) | L3MBTL1SMN1; SMN2ALDH1A1LMNATDP1 | |
| SCHEMBL14495147 | 0.85 | L3MBTL1 (0.46) | L3MBTL1SMN1; SMN2ALDH1A1LMNATDP1 | |
| SCHEMBL6523291 | 0.85 | L3MBTL1 (0.46) | L3MBTL1SMN1; SMN2ALDH1A1LMNATDP1 | |
| SCHEMBL14198846 | 0.82 | SMN1; SMN2 (0.57) | L3MBTL1SMN1; SMN2ALDH1A1LMNATDP1 | |
| SCHEMBL758951 | 0.81 | LMNA (0.64) | SMN1; SMN2ALDH1A1LMNATDP1ENPP2 | |
| SCHEMBL4396839 | 0.79 | L3MBTL1 (0.63) | L3MBTL1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11579674 | 0.78 | L3MBTL1 (0.57) | L3MBTL1SMN1; SMN2ALDH1A1ENPP2 | |
| SCHEMBL6180920 | 0.78 | ENPP2 (0.41) | L3MBTL1SMN1; SMN2ALDH1A1LMNATDP1 | |
| SCHEMBL7356299 | 0.77 | LMNA (0.43) | SMN1; SMN2ALDH1A1LMNATDP1ENPP2 | |
| SCHEMBL15177370 | 0.77 | SMN1; SMN2 (0.43) | L3MBTL1SMN1; SMN2ALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919353-B2 | Substituted 8-arylquinolune PDE4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2005-07-19 | — | — | US | disclosed |
| EP-1404330-B1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-06-01 | — | — | EP | disclosed |
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | PDE12, PDE4A, PDE4B | L3MBTL1 3190/4885SMN1; SMN2 2728/4885ALDH1A1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.